EdgeMarket › What Tcg Crossover Management, Llc reported owning
What Tcg Crossover Management, Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
3.5BPositions
49Quarter
2026-03-31Shown below
49largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| ABVX Abivax S.A. | 721.7M | 20.6% | 6.5M | 114.95 | +59.9% |
| CGON CG Oncology, Inc. | 248.4M | 7.1% | 3.7M | 79.81 | +212.6% |
| TNGX Tango Therapeutics, Inc. | 220.3M | 6.3% | 10.5M | 23.88 | +253.8% |
| COGT Cogent Biosciences, Inc. | 190.4M | 5.4% | 4.9M | 36.73 | +209.6% |
| unmapped CUSIP 152309100 | 170.3M | 4.9% | 4.3M | — | — |
| DNTH Dianthus Therapeutics, Inc. /DE/ | 140.7M | 4.0% | 1.7M | 111.10 | +374.4% |
| TYRA Tyra Biosciences, Inc. | 124.4M | 3.6% | 3.2M | 26.05 | +154.4% |
| IMVT Immunovant, Inc. | 110.7M | 3.2% | 4.5M | 44.37 | +199.4% |
| BCRX BIOCRYST PHARMACEUTICALS INC | 104.9M | 3.0% | 11.0M | 9.55 | +14.0% |
| MIRM Mirum Pharmaceuticals, Inc. | 98.1M | 2.8% | 1.1M | 96.31 | +44.4% |
| VOR Vor Biopharma Inc. | 96.5M | 2.8% | 5.7M | 23.36 | -46.9% |
| SYRE Spyre Therapeutics, Inc. | 95.9M | 2.7% | 1.9M | 106.49 | +551.3% |
| AMLX Amylyx Pharmaceuticals, Inc. | 86.8M | 2.5% | 6.2M | 38.66 | +381.4% |
| IRON Disc Medicine, Inc. | 85.8M | 2.5% | 1.3M | 79.81 | +35.9% |
| DYN Dyne Therapeutics, Inc. | 83.7M | 2.4% | 4.6M | 26.10 | +118.0% |
| GLUE Monte Rosa Therapeutics, Inc. | 76.0M | 2.2% | 4.6M | 14.30 | +222.8% |
| SVRA Savara Inc | 67.5M | 1.9% | 12.4M | 5.59 | +80.9% |
| RVMD Revolution Medicines, Inc. | 56.1M | 1.6% | 576.5K | 209.46 | +479.3% |
| KOD Kodiak Sciences Inc. | 55.1M | 1.6% | 1.4M | 38.33 | +303.5% |
| LBRX LB PHARMACEUTICALS INC | 45.3M | 1.3% | 1.8M | 47.62 | — |
| SRZN Surrozen, Inc./DE | 42.9M | 1.2% | 1.5M | 23.99 | +108.6% |
| ADCT ADC Therapeutics SA | 42.7M | 1.2% | 11.4M | 1.00 | -68.0% |
| RLAY Relay Therapeutics, Inc. | 42.5M | 1.2% | 4.3M | 19.44 | +471.8% |
| FULC Fulcrum Therapeutics, Inc. | 40.3M | 1.2% | 5.2M | 3.83 | -41.7% |
| BHVN Biohaven Ltd. | 39.2M | 1.1% | 4.6M | 13.85 | -5.8% |
| IPSC Century Therapeutics, Inc. | 39.0M | 1.1% | 17.8M | 2.07 | +279.8% |
| TECX Tectonic Therapeutic, Inc. | 37.2M | 1.1% | 1.2M | 37.63 | +56.3% |
| CATX Perspective Therapeutics, Inc. | 33.0M | 0.9% | 7.9M | 3.30 | -2.4% |
| XNCR Xencor Inc | 29.6M | 0.8% | 2.5M | 27.80 | +270.2% |
| TRDA Entrada Therapeutics, Inc. | 28.9M | 0.8% | 2.3M | 7.57 | +42.6% |
| ALXO ALX ONCOLOGY HOLDINGS INC | 26.1M | 0.7% | 13.0M | 2.04 | +145.2% |
| ARVN ARVINAS, INC. | 25.3M | 0.7% | 2.4M | 9.37 | +31.9% |
| JANX Janux Therapeutics, Inc. | 24.9M | 0.7% | 1.8M | 17.39 | -30.1% |
| AGMB Agomab Therapeutics NV | 21.5M | 0.6% | 2.1M | 13.25 | — |
| ALEC Alector, Inc. | 21.5M | 0.6% | 10.0M | 2.36 | +7.3% |
| MBX MBX Biosciences, Inc. | 19.4M | 0.6% | 650.0K | 66.33 | +386.6% |
| SLN Silence Therapeutics plc | 16.0M | 0.5% | 3.0M | 13.27 | +149.0% |
| LQDA Liquidia Corp | 15.2M | 0.4% | 403.0K | 68.62 | +150.9% |
| OCUL OCULAR THERAPEUTIX, INC | 14.0M | 0.4% | 1.6M | 11.08 | -7.4% |
| AVTX Avalo Therapeutics, Inc. | 11.0M | 0.3% | 738.4K | 19.83 | +115.1% |
| URGN UroGen Pharma Ltd. | 7.3M | 0.2% | 405.4K | 46.86 | +142.7% |
| MNPR Monopar Therapeutics | 7.2M | 0.2% | 132.1K | 107.72 | +226.4% |
| CNTX Context Therapeutics Inc. | 7.0M | 0.2% | 2.7M | 0.50 | -44.7% |
| GPCR Structure Therapeutics Inc. | 6.8M | 0.2% | 140.4K | 49.09 | +164.4% |
| CGEM Cullinan Therapeutics, Inc. | 5.8M | 0.2% | 406.8K | 21.68 | +190.2% |
| KRRO Korro Bio, Inc. | 4.7M | 0.1% | 416.3K | 13.18 | -31.6% |
| LONA LeonaBio, Inc. | 4.7M | 0.1% | 464.4K | 7.68 | +92.8% |
| UPB Upstream Bio, Inc. | 1.6M | 0.0% | 181.1K | 6.97 | -57.4% |
| VTGN Vistagen Therapeutics, Inc. | 1.5M | 0.0% | 2.7M | 0.24 | -92.1% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →